US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target.
Both the firms have not disclosed the financial terms of the deal, under which Momenta will pay an upfront fee to AnaptysBio in exchange for an option to acquire antibodies generated by AnaptysBio using its SHM-XEL platform against a specific therapeutic target.
AnaptysBio president and CEO Hamza Suria said the company's platform technology and antibody development capabilities have been strongly validated by numerous successful partnerships.
"We look forward to working with Momenta on the development of these exciting new antibodies for unmet medical needs," Suria said.
AnaptysBio uses somatic hypermutation (SHM) for antibody discovery and optimization.
Currently, the company is developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications.